nodes	percent_of_prediction	percent_of_DWPC	metapath
Alosetron—CYP3A4—Everolimus—kidney cancer	0.096	0.157	CbGbCtD
Alosetron—CYP1A2—Pazopanib—kidney cancer	0.065	0.107	CbGbCtD
Alosetron—CYP3A4—Temsirolimus—kidney cancer	0.0649	0.106	CbGbCtD
Alosetron—CYP2C9—Capecitabine—kidney cancer	0.0611	0.1	CbGbCtD
Alosetron—CYP1A2—Erlotinib—kidney cancer	0.0464	0.076	CbGbCtD
Alosetron—CYP2C9—Paclitaxel—kidney cancer	0.0383	0.0627	CbGbCtD
Alosetron—CYP1A2—Sorafenib—kidney cancer	0.0377	0.0618	CbGbCtD
Alosetron—CYP3A4—Pazopanib—kidney cancer	0.0341	0.0558	CbGbCtD
Alosetron—CYP2C9—Sorafenib—kidney cancer	0.034	0.0557	CbGbCtD
Alosetron—CYP3A4—Erlotinib—kidney cancer	0.0243	0.0398	CbGbCtD
Alosetron—CYP3A4—Paclitaxel—kidney cancer	0.0223	0.0364	CbGbCtD
Alosetron—CYP3A4—Sorafenib—kidney cancer	0.0198	0.0324	CbGbCtD
Alosetron—CYP3A4—Vinblastine—kidney cancer	0.0195	0.032	CbGbCtD
Alosetron—CYP3A4—Vincristine—kidney cancer	0.0192	0.0314	CbGbCtD
Alosetron—CYP3A4—Sunitinib—kidney cancer	0.016	0.0262	CbGbCtD
Alosetron—CYP3A4—Doxorubicin—kidney cancer	0.012	0.0196	CbGbCtD
Alosetron—CYP1A2—urine—kidney cancer	0.00161	0.198	CbGeAlD
Alosetron—CYP2C9—urine—kidney cancer	0.00153	0.188	CbGeAlD
Alosetron—CYP2E1—urine—kidney cancer	0.00145	0.178	CbGeAlD
Alosetron—CYP3A4—urine—kidney cancer	0.00117	0.143	CbGeAlD
Alosetron—Malaise—Dactinomycin—kidney cancer	0.000398	0.00114	CcSEcCtD
Alosetron—Myalgia—Sunitinib—kidney cancer	0.000397	0.00114	CcSEcCtD
Alosetron—Bone pain—Doxorubicin—kidney cancer	0.000396	0.00113	CcSEcCtD
Alosetron—CYP1A2—renal system—kidney cancer	0.000395	0.0485	CbGeAlD
Alosetron—Infection—Sorafenib—kidney cancer	0.000393	0.00113	CcSEcCtD
Alosetron—Fatigue—Everolimus—kidney cancer	0.000393	0.00113	CcSEcCtD
Alosetron—Pain—Vinblastine—kidney cancer	0.000391	0.00112	CcSEcCtD
Alosetron—Constipation—Vinblastine—kidney cancer	0.000391	0.00112	CcSEcCtD
Alosetron—CYP2E1—nephron tubule—kidney cancer	0.000391	0.048	CbGeAlD
Alosetron—Abdominal pain upper—Capecitabine—kidney cancer	0.00039	0.00112	CcSEcCtD
Alosetron—Urinary tract infection—Paclitaxel—kidney cancer	0.00039	0.00112	CcSEcCtD
Alosetron—Constipation—Everolimus—kidney cancer	0.00039	0.00112	CcSEcCtD
Alosetron—Pain—Everolimus—kidney cancer	0.00039	0.00112	CcSEcCtD
Alosetron—Vomiting—Temsirolimus—kidney cancer	0.000389	0.00112	CcSEcCtD
Alosetron—Dry mouth—Sunitinib—kidney cancer	0.000388	0.00111	CcSEcCtD
Alosetron—Rash—Temsirolimus—kidney cancer	0.000386	0.00111	CcSEcCtD
Alosetron—Dermatitis—Temsirolimus—kidney cancer	0.000386	0.00111	CcSEcCtD
Alosetron—Skin disorder—Sorafenib—kidney cancer	0.000384	0.0011	CcSEcCtD
Alosetron—Arrhythmia—Gemcitabine—kidney cancer	0.000384	0.0011	CcSEcCtD
Alosetron—Headache—Temsirolimus—kidney cancer	0.000384	0.0011	CcSEcCtD
Alosetron—Nasopharyngitis—Capecitabine—kidney cancer	0.000382	0.00109	CcSEcCtD
Alosetron—Alopecia—Gemcitabine—kidney cancer	0.00038	0.00109	CcSEcCtD
Alosetron—Fatigue—Erlotinib—kidney cancer	0.000379	0.00109	CcSEcCtD
Alosetron—Infection—Sunitinib—kidney cancer	0.000378	0.00108	CcSEcCtD
Alosetron—Gastritis—Capecitabine—kidney cancer	0.000378	0.00108	CcSEcCtD
Alosetron—Feeling abnormal—Vinblastine—kidney cancer	0.000377	0.00108	CcSEcCtD
Alosetron—Alanine aminotransferase increased—Capecitabine—kidney cancer	0.000376	0.00108	CcSEcCtD
Alosetron—Sinusitis—Paclitaxel—kidney cancer	0.000376	0.00108	CcSEcCtD
Alosetron—Constipation—Erlotinib—kidney cancer	0.000376	0.00108	CcSEcCtD
Alosetron—Pain—Erlotinib—kidney cancer	0.000376	0.00108	CcSEcCtD
Alosetron—Myalgia—Dactinomycin—kidney cancer	0.000376	0.00108	CcSEcCtD
Alosetron—Feeling abnormal—Everolimus—kidney cancer	0.000375	0.00108	CcSEcCtD
Alosetron—Abnormal dreams—Doxorubicin—kidney cancer	0.000375	0.00107	CcSEcCtD
Alosetron—Abdominal distension—Capecitabine—kidney cancer	0.000371	0.00106	CcSEcCtD
Alosetron—Discomfort—Dactinomycin—kidney cancer	0.000371	0.00106	CcSEcCtD
Alosetron—Cystitis noninfective—Doxorubicin—kidney cancer	0.00037	0.00106	CcSEcCtD
Alosetron—Skin disorder—Sunitinib—kidney cancer	0.00037	0.00106	CcSEcCtD
Alosetron—Vomiting—Pazopanib—kidney cancer	0.000367	0.00105	CcSEcCtD
Alosetron—Cystitis—Doxorubicin—kidney cancer	0.000366	0.00105	CcSEcCtD
Alosetron—Colitis—Doxorubicin—kidney cancer	0.000364	0.00104	CcSEcCtD
Alosetron—Rash—Pazopanib—kidney cancer	0.000364	0.00104	CcSEcCtD
Alosetron—Nausea—Temsirolimus—kidney cancer	0.000364	0.00104	CcSEcCtD
Alosetron—Dermatitis—Pazopanib—kidney cancer	0.000363	0.00104	CcSEcCtD
Alosetron—Haemoglobin—Paclitaxel—kidney cancer	0.000362	0.00104	CcSEcCtD
Alosetron—Headache—Pazopanib—kidney cancer	0.000361	0.00104	CcSEcCtD
Alosetron—Musculoskeletal discomfort—Sorafenib—kidney cancer	0.00036	0.00103	CcSEcCtD
Alosetron—Haemorrhage—Paclitaxel—kidney cancer	0.00036	0.00103	CcSEcCtD
Alosetron—Hypoaesthesia—Paclitaxel—kidney cancer	0.000358	0.00103	CcSEcCtD
Alosetron—Infection—Dactinomycin—kidney cancer	0.000358	0.00103	CcSEcCtD
Alosetron—CYP2E1—renal system—kidney cancer	0.000355	0.0436	CbGeAlD
Alosetron—Abdominal discomfort—Capecitabine—kidney cancer	0.000354	0.00101	CcSEcCtD
Alosetron—Ill-defined disorder—Gemcitabine—kidney cancer	0.000347	0.000995	CcSEcCtD
Alosetron—Musculoskeletal discomfort—Sunitinib—kidney cancer	0.000347	0.000994	CcSEcCtD
Alosetron—CYP2E1—kidney—kidney cancer	0.000343	0.0421	CbGeAlD
Alosetron—Upper respiratory tract infection—Capecitabine—kidney cancer	0.000343	0.000983	CcSEcCtD
Alosetron—Nausea—Pazopanib—kidney cancer	0.000343	0.000983	CcSEcCtD
Alosetron—Bladder pain—Doxorubicin—kidney cancer	0.000343	0.000983	CcSEcCtD
Alosetron—Fatigue—Sorafenib—kidney cancer	0.000341	0.000978	CcSEcCtD
Alosetron—Hypertension—Vincristine—kidney cancer	0.00034	0.000976	CcSEcCtD
Alosetron—Pain—Sorafenib—kidney cancer	0.000338	0.00097	CcSEcCtD
Alosetron—Constipation—Sorafenib—kidney cancer	0.000338	0.00097	CcSEcCtD
Alosetron—Malaise—Gemcitabine—kidney cancer	0.000337	0.000967	CcSEcCtD
Alosetron—Hypersensitivity—Vinblastine—kidney cancer	0.000337	0.000966	CcSEcCtD
Alosetron—Myalgia—Vincristine—kidney cancer	0.000336	0.000963	CcSEcCtD
Alosetron—Hypersensitivity—Everolimus—kidney cancer	0.000336	0.000962	CcSEcCtD
Alosetron—CYP2E1—cortex of kidney—kidney cancer	0.000334	0.041	CbGeAlD
Alosetron—Hyperglycaemia—Capecitabine—kidney cancer	0.000333	0.000954	CcSEcCtD
Alosetron—Musculoskeletal discomfort—Dactinomycin—kidney cancer	0.000328	0.000941	CcSEcCtD
Alosetron—Asthenia—Vinblastine—kidney cancer	0.000328	0.000941	CcSEcCtD
Alosetron—Fatigue—Sunitinib—kidney cancer	0.000328	0.000941	CcSEcCtD
Alosetron—Depression—Capecitabine—kidney cancer	0.000328	0.00094	CcSEcCtD
Alosetron—Asthenia—Everolimus—kidney cancer	0.000327	0.000937	CcSEcCtD
Alosetron—Cough—Gemcitabine—kidney cancer	0.000326	0.000936	CcSEcCtD
Alosetron—Pain—Sunitinib—kidney cancer	0.000325	0.000933	CcSEcCtD
Alosetron—Constipation—Sunitinib—kidney cancer	0.000325	0.000933	CcSEcCtD
Alosetron—Hypertension—Gemcitabine—kidney cancer	0.000323	0.000926	CcSEcCtD
Alosetron—Arrhythmia—Paclitaxel—kidney cancer	0.000321	0.000922	CcSEcCtD
Alosetron—Jaundice—Capecitabine—kidney cancer	0.000321	0.000919	CcSEcCtD
Alosetron—Infection—Vincristine—kidney cancer	0.00032	0.000917	CcSEcCtD
Alosetron—Urinary tract infection—Capecitabine—kidney cancer	0.00032	0.000917	CcSEcCtD
Alosetron—Myalgia—Gemcitabine—kidney cancer	0.000318	0.000913	CcSEcCtD
Alosetron—Alopecia—Paclitaxel—kidney cancer	0.000318	0.000912	CcSEcCtD
Alosetron—Asthenia—Erlotinib—kidney cancer	0.000315	0.000904	CcSEcCtD
Alosetron—Discomfort—Gemcitabine—kidney cancer	0.000315	0.000902	CcSEcCtD
Alosetron—Urticaria—Sorafenib—kidney cancer	0.000314	0.000901	CcSEcCtD
Alosetron—Hyperhidrosis—Vincristine—kidney cancer	0.000311	0.000892	CcSEcCtD
Alosetron—Fatigue—Dactinomycin—kidney cancer	0.000311	0.000891	CcSEcCtD
Alosetron—Flatulence—Paclitaxel—kidney cancer	0.000309	0.000885	CcSEcCtD
Alosetron—Pain—Dactinomycin—kidney cancer	0.000308	0.000883	CcSEcCtD
Alosetron—Eczema—Doxorubicin—kidney cancer	0.000306	0.000878	CcSEcCtD
Alosetron—Infection—Gemcitabine—kidney cancer	0.000303	0.00087	CcSEcCtD
Alosetron—Muscle spasms—Paclitaxel—kidney cancer	0.000301	0.000864	CcSEcCtD
Alosetron—Feeling abnormal—Dactinomycin—kidney cancer	0.000297	0.000851	CcSEcCtD
Alosetron—Haemoglobin—Capecitabine—kidney cancer	0.000297	0.000851	CcSEcCtD
Alosetron—Skin disorder—Gemcitabine—kidney cancer	0.000297	0.00085	CcSEcCtD
Alosetron—Hepatitis—Capecitabine—kidney cancer	0.000295	0.000847	CcSEcCtD
Alosetron—Haemorrhage—Capecitabine—kidney cancer	0.000295	0.000847	CcSEcCtD
Alosetron—Hyperhidrosis—Gemcitabine—kidney cancer	0.000295	0.000846	CcSEcCtD
Alosetron—Hypoaesthesia—Capecitabine—kidney cancer	0.000294	0.000842	CcSEcCtD
Alosetron—Tremor—Paclitaxel—kidney cancer	0.000293	0.000841	CcSEcCtD
Alosetron—Musculoskeletal discomfort—Vincristine—kidney cancer	0.000293	0.000841	CcSEcCtD
Alosetron—Hypersensitivity—Sorafenib—kidney cancer	0.000291	0.000835	CcSEcCtD
Alosetron—Vomiting—Vinblastine—kidney cancer	0.000291	0.000834	CcSEcCtD
Alosetron—Ill-defined disorder—Paclitaxel—kidney cancer	0.000291	0.000833	CcSEcCtD
Alosetron—Vomiting—Everolimus—kidney cancer	0.00029	0.000831	CcSEcCtD
Alosetron—Rash—Everolimus—kidney cancer	0.000287	0.000824	CcSEcCtD
Alosetron—Dermatitis—Everolimus—kidney cancer	0.000287	0.000823	CcSEcCtD
Alosetron—Headache—Vinblastine—kidney cancer	0.000286	0.000822	CcSEcCtD
Alosetron—CYP3A4—renal system—kidney cancer	0.000286	0.0351	CbGeAlD
Alosetron—Headache—Everolimus—kidney cancer	0.000285	0.000818	CcSEcCtD
Alosetron—Asthenia—Sorafenib—kidney cancer	0.000284	0.000814	CcSEcCtD
Alosetron—Malaise—Paclitaxel—kidney cancer	0.000282	0.00081	CcSEcCtD
Alosetron—Hypoglycaemia—Doxorubicin—kidney cancer	0.000282	0.000808	CcSEcCtD
Alosetron—Hypersensitivity—Sunitinib—kidney cancer	0.00028	0.000804	CcSEcCtD
Alosetron—Vomiting—Erlotinib—kidney cancer	0.000279	0.000801	CcSEcCtD
Alosetron—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.000278	0.000798	CcSEcCtD
Alosetron—Fatigue—Vincristine—kidney cancer	0.000277	0.000796	CcSEcCtD
Alosetron—Rash—Erlotinib—kidney cancer	0.000277	0.000795	CcSEcCtD
Alosetron—Dermatitis—Erlotinib—kidney cancer	0.000277	0.000794	CcSEcCtD
Alosetron—CYP3A4—kidney—kidney cancer	0.000276	0.0339	CbGeAlD
Alosetron—Headache—Erlotinib—kidney cancer	0.000275	0.00079	CcSEcCtD
Alosetron—Pain—Vincristine—kidney cancer	0.000275	0.000789	CcSEcCtD
Alosetron—Constipation—Vincristine—kidney cancer	0.000275	0.000789	CcSEcCtD
Alosetron—Cough—Paclitaxel—kidney cancer	0.000273	0.000784	CcSEcCtD
Alosetron—Asthenia—Sunitinib—kidney cancer	0.000273	0.000783	CcSEcCtD
Alosetron—Nausea—Vinblastine—kidney cancer	0.000272	0.000779	CcSEcCtD
Alosetron—Nausea—Everolimus—kidney cancer	0.000271	0.000776	CcSEcCtD
Alosetron—Hypertension—Paclitaxel—kidney cancer	0.00027	0.000775	CcSEcCtD
Alosetron—Myalgia—Paclitaxel—kidney cancer	0.000267	0.000765	CcSEcCtD
Alosetron—Anxiety—Paclitaxel—kidney cancer	0.000266	0.000762	CcSEcCtD
Alosetron—Hypersensitivity—Dactinomycin—kidney cancer	0.000265	0.000761	CcSEcCtD
Alosetron—Arrhythmia—Capecitabine—kidney cancer	0.000264	0.000756	CcSEcCtD
Alosetron—Discomfort—Paclitaxel—kidney cancer	0.000263	0.000755	CcSEcCtD
Alosetron—Fatigue—Gemcitabine—kidney cancer	0.000263	0.000755	CcSEcCtD
Alosetron—Pain—Gemcitabine—kidney cancer	0.000261	0.000749	CcSEcCtD
Alosetron—Constipation—Gemcitabine—kidney cancer	0.000261	0.000749	CcSEcCtD
Alosetron—Nausea—Erlotinib—kidney cancer	0.000261	0.000749	CcSEcCtD
Alosetron—Alopecia—Capecitabine—kidney cancer	0.000261	0.000748	CcSEcCtD
Alosetron—Dry mouth—Paclitaxel—kidney cancer	0.000261	0.000748	CcSEcCtD
Alosetron—Asthenia—Dactinomycin—kidney cancer	0.000258	0.000741	CcSEcCtD
Alosetron—Confusional state—Paclitaxel—kidney cancer	0.000258	0.000739	CcSEcCtD
Alosetron—Infection—Paclitaxel—kidney cancer	0.000254	0.000728	CcSEcCtD
Alosetron—Flatulence—Capecitabine—kidney cancer	0.000253	0.000726	CcSEcCtD
Alosetron—Feeling abnormal—Gemcitabine—kidney cancer	0.000252	0.000721	CcSEcCtD
Alosetron—Vomiting—Sorafenib—kidney cancer	0.000251	0.000721	CcSEcCtD
Alosetron—Abdominal pain upper—Doxorubicin—kidney cancer	0.000251	0.000721	CcSEcCtD
Alosetron—Rash—Sorafenib—kidney cancer	0.000249	0.000715	CcSEcCtD
Alosetron—Dermatitis—Sorafenib—kidney cancer	0.000249	0.000714	CcSEcCtD
Alosetron—Skin disorder—Paclitaxel—kidney cancer	0.000248	0.000712	CcSEcCtD
Alosetron—Headache—Sorafenib—kidney cancer	0.000248	0.00071	CcSEcCtD
Alosetron—Muscle spasms—Capecitabine—kidney cancer	0.000247	0.000709	CcSEcCtD
Alosetron—Hyperhidrosis—Paclitaxel—kidney cancer	0.000247	0.000709	CcSEcCtD
Alosetron—Nasopharyngitis—Doxorubicin—kidney cancer	0.000246	0.000705	CcSEcCtD
Alosetron—Gastritis—Doxorubicin—kidney cancer	0.000243	0.000698	CcSEcCtD
Alosetron—Alanine aminotransferase increased—Doxorubicin—kidney cancer	0.000243	0.000696	CcSEcCtD
Alosetron—Vomiting—Sunitinib—kidney cancer	0.000242	0.000694	CcSEcCtD
Alosetron—Tremor—Capecitabine—kidney cancer	0.000241	0.000691	CcSEcCtD
Alosetron—Rash—Sunitinib—kidney cancer	0.00024	0.000688	CcSEcCtD
Alosetron—Dermatitis—Sunitinib—kidney cancer	0.00024	0.000687	CcSEcCtD
Alosetron—Abdominal distension—Doxorubicin—kidney cancer	0.000239	0.000686	CcSEcCtD
Alosetron—Ill-defined disorder—Capecitabine—kidney cancer	0.000238	0.000684	CcSEcCtD
Alosetron—Headache—Sunitinib—kidney cancer	0.000238	0.000684	CcSEcCtD
Alosetron—Hypersensitivity—Vincristine—kidney cancer	0.000237	0.00068	CcSEcCtD
Alosetron—Nausea—Sorafenib—kidney cancer	0.000235	0.000674	CcSEcCtD
Alosetron—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.000233	0.000668	CcSEcCtD
Alosetron—Malaise—Capecitabine—kidney cancer	0.000232	0.000665	CcSEcCtD
Alosetron—Asthenia—Vincristine—kidney cancer	0.000231	0.000662	CcSEcCtD
Alosetron—Vomiting—Dactinomycin—kidney cancer	0.000229	0.000657	CcSEcCtD
Alosetron—Rash—Dactinomycin—kidney cancer	0.000227	0.000651	CcSEcCtD
Alosetron—Nausea—Sunitinib—kidney cancer	0.000226	0.000648	CcSEcCtD
Alosetron—Cough—Capecitabine—kidney cancer	0.000224	0.000643	CcSEcCtD
Alosetron—Hypertension—Capecitabine—kidney cancer	0.000222	0.000636	CcSEcCtD
Alosetron—Upper respiratory tract infection—Doxorubicin—kidney cancer	0.000221	0.000634	CcSEcCtD
Alosetron—Fatigue—Paclitaxel—kidney cancer	0.00022	0.000632	CcSEcCtD
Alosetron—Pollakiuria—Doxorubicin—kidney cancer	0.00022	0.00063	CcSEcCtD
Alosetron—Asthenia—Gemcitabine—kidney cancer	0.000219	0.000628	CcSEcCtD
Alosetron—Myalgia—Capecitabine—kidney cancer	0.000219	0.000628	CcSEcCtD
Alosetron—Pain—Paclitaxel—kidney cancer	0.000219	0.000627	CcSEcCtD
Alosetron—Constipation—Paclitaxel—kidney cancer	0.000219	0.000627	CcSEcCtD
Alosetron—Anxiety—Capecitabine—kidney cancer	0.000218	0.000625	CcSEcCtD
Alosetron—Discomfort—Capecitabine—kidney cancer	0.000216	0.00062	CcSEcCtD
Alosetron—Hyperglycaemia—Doxorubicin—kidney cancer	0.000214	0.000615	CcSEcCtD
Alosetron—Dry mouth—Capecitabine—kidney cancer	0.000214	0.000614	CcSEcCtD
Alosetron—Nausea—Dactinomycin—kidney cancer	0.000214	0.000614	CcSEcCtD
Alosetron—Confusional state—Capecitabine—kidney cancer	0.000211	0.000607	CcSEcCtD
Alosetron—Feeling abnormal—Paclitaxel—kidney cancer	0.000211	0.000604	CcSEcCtD
Alosetron—Infection—Capecitabine—kidney cancer	0.000208	0.000598	CcSEcCtD
Alosetron—Jaundice—Doxorubicin—kidney cancer	0.000207	0.000593	CcSEcCtD
Alosetron—Urinary tract infection—Doxorubicin—kidney cancer	0.000206	0.000591	CcSEcCtD
Alosetron—Vomiting—Vincristine—kidney cancer	0.000205	0.000587	CcSEcCtD
Alosetron—Skin disorder—Capecitabine—kidney cancer	0.000204	0.000584	CcSEcCtD
Alosetron—Sweating—Doxorubicin—kidney cancer	0.000203	0.000583	CcSEcCtD
Alosetron—Urticaria—Paclitaxel—kidney cancer	0.000203	0.000582	CcSEcCtD
Alosetron—Rash—Vincristine—kidney cancer	0.000203	0.000582	CcSEcCtD
Alosetron—Hyperhidrosis—Capecitabine—kidney cancer	0.000203	0.000582	CcSEcCtD
Alosetron—Dermatitis—Vincristine—kidney cancer	0.000203	0.000581	CcSEcCtD
Alosetron—Headache—Vincristine—kidney cancer	0.000202	0.000578	CcSEcCtD
Alosetron—Sinusitis—Doxorubicin—kidney cancer	0.000199	0.00057	CcSEcCtD
Alosetron—Vomiting—Gemcitabine—kidney cancer	0.000194	0.000557	CcSEcCtD
Alosetron—Rash—Gemcitabine—kidney cancer	0.000192	0.000552	CcSEcCtD
Alosetron—Dermatitis—Gemcitabine—kidney cancer	0.000192	0.000552	CcSEcCtD
Alosetron—Haemoglobin—Doxorubicin—kidney cancer	0.000191	0.000549	CcSEcCtD
Alosetron—Headache—Gemcitabine—kidney cancer	0.000191	0.000548	CcSEcCtD
Alosetron—Nausea—Vincristine—kidney cancer	0.000191	0.000548	CcSEcCtD
Alosetron—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.000191	0.000548	CcSEcCtD
Alosetron—Haemorrhage—Doxorubicin—kidney cancer	0.00019	0.000546	CcSEcCtD
Alosetron—Hepatitis—Doxorubicin—kidney cancer	0.00019	0.000546	CcSEcCtD
Alosetron—Hypoaesthesia—Doxorubicin—kidney cancer	0.000189	0.000543	CcSEcCtD
Alosetron—Hypersensitivity—Paclitaxel—kidney cancer	0.000188	0.00054	CcSEcCtD
Alosetron—Asthenia—Paclitaxel—kidney cancer	0.000183	0.000526	CcSEcCtD
Alosetron—Nausea—Gemcitabine—kidney cancer	0.000181	0.00052	CcSEcCtD
Alosetron—Fatigue—Capecitabine—kidney cancer	0.000181	0.000519	CcSEcCtD
Alosetron—Pain—Capecitabine—kidney cancer	0.000179	0.000514	CcSEcCtD
Alosetron—Constipation—Capecitabine—kidney cancer	0.000179	0.000514	CcSEcCtD
Alosetron—Feeling abnormal—Capecitabine—kidney cancer	0.000173	0.000496	CcSEcCtD
Alosetron—Arrhythmia—Doxorubicin—kidney cancer	0.00017	0.000488	CcSEcCtD
Alosetron—Alopecia—Doxorubicin—kidney cancer	0.000168	0.000482	CcSEcCtD
Alosetron—Urticaria—Capecitabine—kidney cancer	0.000167	0.000478	CcSEcCtD
Alosetron—Flatulence—Doxorubicin—kidney cancer	0.000163	0.000468	CcSEcCtD
Alosetron—Vomiting—Paclitaxel—kidney cancer	0.000163	0.000466	CcSEcCtD
Alosetron—Rash—Paclitaxel—kidney cancer	0.000161	0.000462	CcSEcCtD
Alosetron—Dermatitis—Paclitaxel—kidney cancer	0.000161	0.000462	CcSEcCtD
Alosetron—Headache—Paclitaxel—kidney cancer	0.00016	0.000459	CcSEcCtD
Alosetron—Muscle spasms—Doxorubicin—kidney cancer	0.000159	0.000457	CcSEcCtD
Alosetron—Hypersensitivity—Capecitabine—kidney cancer	0.000155	0.000443	CcSEcCtD
Alosetron—Ill-defined disorder—Doxorubicin—kidney cancer	0.000154	0.000441	CcSEcCtD
Alosetron—Nausea—Paclitaxel—kidney cancer	0.000152	0.000435	CcSEcCtD
Alosetron—Asthenia—Capecitabine—kidney cancer	0.00015	0.000432	CcSEcCtD
Alosetron—Malaise—Doxorubicin—kidney cancer	0.000149	0.000428	CcSEcCtD
Alosetron—Cough—Doxorubicin—kidney cancer	0.000145	0.000415	CcSEcCtD
Alosetron—Hypertension—Doxorubicin—kidney cancer	0.000143	0.00041	CcSEcCtD
Alosetron—Myalgia—Doxorubicin—kidney cancer	0.000141	0.000404	CcSEcCtD
Alosetron—Anxiety—Doxorubicin—kidney cancer	0.000141	0.000403	CcSEcCtD
Alosetron—Discomfort—Doxorubicin—kidney cancer	0.000139	0.0004	CcSEcCtD
Alosetron—Dry mouth—Doxorubicin—kidney cancer	0.000138	0.000396	CcSEcCtD
Alosetron—Confusional state—Doxorubicin—kidney cancer	0.000136	0.000391	CcSEcCtD
Alosetron—Infection—Doxorubicin—kidney cancer	0.000134	0.000385	CcSEcCtD
Alosetron—Vomiting—Capecitabine—kidney cancer	0.000133	0.000382	CcSEcCtD
Alosetron—Rash—Capecitabine—kidney cancer	0.000132	0.000379	CcSEcCtD
Alosetron—Dermatitis—Capecitabine—kidney cancer	0.000132	0.000379	CcSEcCtD
Alosetron—Headache—Capecitabine—kidney cancer	0.000131	0.000377	CcSEcCtD
Alosetron—Skin disorder—Doxorubicin—kidney cancer	0.000131	0.000377	CcSEcCtD
Alosetron—Hyperhidrosis—Doxorubicin—kidney cancer	0.000131	0.000375	CcSEcCtD
Alosetron—Nausea—Capecitabine—kidney cancer	0.000125	0.000357	CcSEcCtD
Alosetron—Musculoskeletal discomfort—Doxorubicin—kidney cancer	0.000123	0.000353	CcSEcCtD
Alosetron—HTR3A—Ion channel transport—RAF1—kidney cancer	0.00012	0.00369	CbGpPWpGaD
Alosetron—Fatigue—Doxorubicin—kidney cancer	0.000117	0.000334	CcSEcCtD
Alosetron—Constipation—Doxorubicin—kidney cancer	0.000116	0.000332	CcSEcCtD
Alosetron—Pain—Doxorubicin—kidney cancer	0.000116	0.000332	CcSEcCtD
Alosetron—CYP2C9—Biological oxidations—ALDH1A1—kidney cancer	0.000116	0.00356	CbGpPWpGaD
Alosetron—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—kidney cancer	0.000113	0.00348	CbGpPWpGaD
Alosetron—Feeling abnormal—Doxorubicin—kidney cancer	0.000111	0.00032	CcSEcCtD
Alosetron—CYP2C9—Arachidonic acid metabolism—CYP1A1—kidney cancer	0.00011	0.0034	CbGpPWpGaD
Alosetron—CYP2E1—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	0.00011	0.00338	CbGpPWpGaD
Alosetron—HTR3A—SIDS Susceptibility Pathways—JUN—kidney cancer	0.000108	0.00332	CbGpPWpGaD
Alosetron—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—kidney cancer	0.000107	0.00331	CbGpPWpGaD
Alosetron—Urticaria—Doxorubicin—kidney cancer	0.000107	0.000308	CcSEcCtD
Alosetron—HTR3A—SIDS Susceptibility Pathways—CTNNB1—kidney cancer	0.000107	0.00329	CbGpPWpGaD
Alosetron—CYP1A2—Phase 1 - Functionalization of compounds—PTGS1—kidney cancer	0.000102	0.00316	CbGpPWpGaD
Alosetron—CYP2E1—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	0.000101	0.00311	CbGpPWpGaD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1A1—kidney cancer	0.000101	0.0031	CbGpPWpGaD
Alosetron—CYP1A2—Tryptophan metabolism—CYP1A1—kidney cancer	0.000101	0.0031	CbGpPWpGaD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor—CYP1A1—kidney cancer	0.000101	0.0031	CbGpPWpGaD
Alosetron—Hypersensitivity—Doxorubicin—kidney cancer	9.96e-05	0.000286	CcSEcCtD
Alosetron—CYP1A2—Phase II conjugation—GSTT1—kidney cancer	9.92e-05	0.00306	CbGpPWpGaD
Alosetron—CYP1A2—Biological oxidations—ALDH1A1—kidney cancer	9.87e-05	0.00304	CbGpPWpGaD
Alosetron—Asthenia—Doxorubicin—kidney cancer	9.7e-05	0.000278	CcSEcCtD
Alosetron—HTR3A—Transmembrane transport of small molecules—SLC5A5—kidney cancer	9.66e-05	0.00298	CbGpPWpGaD
Alosetron—CYP2E1—Biological oxidations—GSTT1—kidney cancer	9.65e-05	0.00298	CbGpPWpGaD
Alosetron—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	9.52e-05	0.00294	CbGpPWpGaD
Alosetron—CYP1A2—Arachidonic acid metabolism—CYP1A1—kidney cancer	9.41e-05	0.0029	CbGpPWpGaD
Alosetron—HTR3A—SIDS Susceptibility Pathways—VEGFA—kidney cancer	9.4e-05	0.0029	CbGpPWpGaD
Alosetron—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	9.39e-05	0.0029	CbGpPWpGaD
Alosetron—HTR3A—Transmembrane transport of small molecules—SLC2A1—kidney cancer	9.33e-05	0.00288	CbGpPWpGaD
Alosetron—CYP2E1—Biological oxidations—PTGS1—kidney cancer	9.04e-05	0.00279	CbGpPWpGaD
Alosetron—Vomiting—Doxorubicin—kidney cancer	8.6e-05	0.000247	CcSEcCtD
Alosetron—Rash—Doxorubicin—kidney cancer	8.52e-05	0.000244	CcSEcCtD
Alosetron—Dermatitis—Doxorubicin—kidney cancer	8.52e-05	0.000244	CcSEcCtD
Alosetron—Headache—Doxorubicin—kidney cancer	8.47e-05	0.000243	CcSEcCtD
Alosetron—CYP2E1—Phase 1 - Functionalization of compounds—POMC—kidney cancer	8.18e-05	0.00252	CbGpPWpGaD
Alosetron—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	8.13e-05	0.00251	CbGpPWpGaD
Alosetron—Nausea—Doxorubicin—kidney cancer	8.03e-05	0.00023	CcSEcCtD
Alosetron—CYP1A2—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	8.03e-05	0.00248	CbGpPWpGaD
Alosetron—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—kidney cancer	7.9e-05	0.00244	CbGpPWpGaD
Alosetron—CYP3A4—Tryptophan metabolism—CYP1A1—kidney cancer	7.76e-05	0.00239	CbGpPWpGaD
Alosetron—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	7.72e-05	0.00238	CbGpPWpGaD
Alosetron—CYP3A4—Biological oxidations—ALDH1A1—kidney cancer	7.62e-05	0.00235	CbGpPWpGaD
Alosetron—CYP2E1—Vitamin A and Carotenoid Metabolism—MAPK1—kidney cancer	7.45e-05	0.0023	CbGpPWpGaD
Alosetron—HTR3A—Transmembrane transport of small molecules—ABCB1—kidney cancer	7.37e-05	0.00227	CbGpPWpGaD
Alosetron—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	7.1e-05	0.00219	CbGpPWpGaD
Alosetron—CYP1A2—Phase II conjugation—GSTP1—kidney cancer	6.87e-05	0.00212	CbGpPWpGaD
Alosetron—CYP2C9—Biological oxidations—GSTT1—kidney cancer	6.79e-05	0.00209	CbGpPWpGaD
Alosetron—CYP2E1—Biological oxidations—GSTP1—kidney cancer	6.69e-05	0.00206	CbGpPWpGaD
Alosetron—CYP2E1—Metapathway biotransformation—GSTP1—kidney cancer	6.6e-05	0.00203	CbGpPWpGaD
Alosetron—CYP1A2—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	6.59e-05	0.00203	CbGpPWpGaD
Alosetron—CYP2C9—Arachidonic acid metabolism—PTGS2—kidney cancer	6.55e-05	0.00202	CbGpPWpGaD
Alosetron—CYP2C9—Biological oxidations—PTGS1—kidney cancer	6.36e-05	0.00196	CbGpPWpGaD
Alosetron—CYP1A2—Phase II conjugation—GSTM1—kidney cancer	6.32e-05	0.00195	CbGpPWpGaD
Alosetron—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	6.28e-05	0.00194	CbGpPWpGaD
Alosetron—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	6.2e-05	0.00191	CbGpPWpGaD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor—RAF1—kidney cancer	6.18e-05	0.00191	CbGpPWpGaD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor—RELA—kidney cancer	6.16e-05	0.0019	CbGpPWpGaD
Alosetron—CYP2E1—Biological oxidations—GSTM1—kidney cancer	6.15e-05	0.0019	CbGpPWpGaD
Alosetron—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	6.06e-05	0.00187	CbGpPWpGaD
Alosetron—CYP2E1—Metapathway biotransformation—GSTM1—kidney cancer	6.06e-05	0.00187	CbGpPWpGaD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—kidney cancer	5.98e-05	0.00185	CbGpPWpGaD
Alosetron—CYP2E1—Biological oxidations—CYP1A1—kidney cancer	5.83e-05	0.0018	CbGpPWpGaD
Alosetron—CYP1A2—Biological oxidations—GSTT1—kidney cancer	5.8e-05	0.00179	CbGpPWpGaD
Alosetron—CYP2C9—Phase 1 - Functionalization of compounds—POMC—kidney cancer	5.75e-05	0.00177	CbGpPWpGaD
Alosetron—CYP2E1—Metapathway biotransformation—CYP1A1—kidney cancer	5.75e-05	0.00177	CbGpPWpGaD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—kidney cancer	5.67e-05	0.00175	CbGpPWpGaD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—kidney cancer	5.67e-05	0.00175	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—GLIPR1—kidney cancer	5.61e-05	0.00173	CbGpPWpGaD
Alosetron—CYP1A2—Arachidonic acid metabolism—PTGS2—kidney cancer	5.6e-05	0.00173	CbGpPWpGaD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—kidney cancer	5.55e-05	0.00171	CbGpPWpGaD
Alosetron—CYP1A2—Biological oxidations—PTGS1—kidney cancer	5.44e-05	0.00168	CbGpPWpGaD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—kidney cancer	5.39e-05	0.00166	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—ACY1—kidney cancer	5.13e-05	0.00158	CbGpPWpGaD
Alosetron—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	5.09e-05	0.00157	CbGpPWpGaD
Alosetron—CYP1A2—Phase 1 - Functionalization of compounds—POMC—kidney cancer	4.92e-05	0.00152	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—GLIPR1—kidney cancer	4.8e-05	0.00148	CbGpPWpGaD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—kidney cancer	4.71e-05	0.00145	CbGpPWpGaD
Alosetron—CYP2C9—Biological oxidations—GSTP1—kidney cancer	4.71e-05	0.00145	CbGpPWpGaD
Alosetron—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	4.68e-05	0.00144	CbGpPWpGaD
Alosetron—CYP2C9—Metapathway biotransformation—GSTP1—kidney cancer	4.64e-05	0.00143	CbGpPWpGaD
Alosetron—CYP3A4—Biological oxidations—GSTT1—kidney cancer	4.48e-05	0.00138	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—PDHB—kidney cancer	4.36e-05	0.00134	CbGpPWpGaD
Alosetron—CYP2E1—Biological oxidations—POMC—kidney cancer	4.34e-05	0.00134	CbGpPWpGaD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor—MYC—kidney cancer	4.34e-05	0.00134	CbGpPWpGaD
Alosetron—CYP2C9—Biological oxidations—GSTM1—kidney cancer	4.32e-05	0.00133	CbGpPWpGaD
Alosetron—CYP2C9—Metapathway biotransformation—GSTM1—kidney cancer	4.26e-05	0.00132	CbGpPWpGaD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—kidney cancer	4.24e-05	0.00131	CbGpPWpGaD
Alosetron—CYP3A4—Biological oxidations—PTGS1—kidney cancer	4.2e-05	0.00129	CbGpPWpGaD
Alosetron—HTR3A—Transmembrane transport of small molecules—RAF1—kidney cancer	4.17e-05	0.00129	CbGpPWpGaD
Alosetron—CYP2C9—Biological oxidations—CYP1A1—kidney cancer	4.1e-05	0.00126	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—CCBL1—kidney cancer	4.1e-05	0.00126	CbGpPWpGaD
Alosetron—CYP2C9—Metapathway biotransformation—CYP1A1—kidney cancer	4.04e-05	0.00125	CbGpPWpGaD
Alosetron—CYP1A2—Biological oxidations—GSTP1—kidney cancer	4.02e-05	0.00124	CbGpPWpGaD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—kidney cancer	4.01e-05	0.00124	CbGpPWpGaD
Alosetron—CYP1A2—Metapathway biotransformation—GSTP1—kidney cancer	3.97e-05	0.00122	CbGpPWpGaD
Alosetron—CYP3A4—Phase 1 - Functionalization of compounds—POMC—kidney cancer	3.79e-05	0.00117	CbGpPWpGaD
Alosetron—CYP1A2—Biological oxidations—GSTM1—kidney cancer	3.69e-05	0.00114	CbGpPWpGaD
Alosetron—CYP1A2—Metapathway biotransformation—GSTM1—kidney cancer	3.64e-05	0.00112	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—ACY1—kidney cancer	3.61e-05	0.00111	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—GLIPR1—kidney cancer	3.55e-05	0.0011	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—PPAT—kidney cancer	3.55e-05	0.0011	CbGpPWpGaD
Alosetron—CYP1A2—Biological oxidations—CYP1A1—kidney cancer	3.5e-05	0.00108	CbGpPWpGaD
Alosetron—CYP1A2—Metapathway biotransformation—CYP1A1—kidney cancer	3.45e-05	0.00107	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—FH—kidney cancer	3.3e-05	0.00102	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—APRT—kidney cancer	3.3e-05	0.00102	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—GPC3—kidney cancer	3.11e-05	0.000958	CbGpPWpGaD
Alosetron—CYP3A4—Biological oxidations—GSTP1—kidney cancer	3.1e-05	0.000957	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—ACY1—kidney cancer	3.08e-05	0.00095	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	3.07e-05	0.000948	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—PDHB—kidney cancer	3.07e-05	0.000946	CbGpPWpGaD
Alosetron—CYP3A4—Metapathway biotransformation—GSTP1—kidney cancer	3.06e-05	0.000944	CbGpPWpGaD
Alosetron—CYP2C9—Biological oxidations—POMC—kidney cancer	3.06e-05	0.000943	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—CA2—kidney cancer	3.02e-05	0.000932	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—ALAD—kidney cancer	2.94e-05	0.000908	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—CCBL1—kidney cancer	2.88e-05	0.000889	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—ST3GAL2—kidney cancer	2.87e-05	0.000886	CbGpPWpGaD
Alosetron—CYP3A4—Biological oxidations—GSTM1—kidney cancer	2.85e-05	0.00088	CbGpPWpGaD
Alosetron—CYP3A4—Metapathway biotransformation—GSTM1—kidney cancer	2.81e-05	0.000867	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—ALDH1A1—kidney cancer	2.81e-05	0.000866	CbGpPWpGaD
Alosetron—CYP3A4—Biological oxidations—CYP1A1—kidney cancer	2.7e-05	0.000834	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—PGK1—kidney cancer	2.69e-05	0.00083	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—SLC5A3—kidney cancer	2.69e-05	0.00083	CbGpPWpGaD
Alosetron—CYP3A4—Metapathway biotransformation—CYP1A1—kidney cancer	2.67e-05	0.000822	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—LDHB—kidney cancer	2.64e-05	0.000814	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	2.63e-05	0.00081	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—PDHB—kidney cancer	2.62e-05	0.000808	CbGpPWpGaD
Alosetron—CYP1A2—Biological oxidations—POMC—kidney cancer	2.61e-05	0.000805	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	2.61e-05	0.000804	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—PPAT—kidney cancer	2.5e-05	0.000771	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—GLIPR1—kidney cancer	2.5e-05	0.000771	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	2.47e-05	0.000761	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—CCBL1—kidney cancer	2.46e-05	0.00076	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	2.44e-05	0.000753	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—ACY1—kidney cancer	2.38e-05	0.000733	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—FH—kidney cancer	2.32e-05	0.000717	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—APRT—kidney cancer	2.32e-05	0.000717	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—CA9—kidney cancer	2.29e-05	0.000706	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	2.27e-05	0.0007	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	2.23e-05	0.000687	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—GPC3—kidney cancer	2.18e-05	0.000674	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—PPAT—kidney cancer	2.14e-05	0.000659	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—GLIPR1—kidney cancer	2.14e-05	0.000659	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—CA2—kidney cancer	2.13e-05	0.000655	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	2.11e-05	0.00065	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	2.09e-05	0.000644	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—ALAD—kidney cancer	2.07e-05	0.000639	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—PDHB—kidney cancer	2.02e-05	0.000624	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—ST3GAL2—kidney cancer	2.02e-05	0.000623	CbGpPWpGaD
Alosetron—CYP3A4—Biological oxidations—POMC—kidney cancer	2.02e-05	0.000622	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—APRT—kidney cancer	1.99e-05	0.000612	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—FH—kidney cancer	1.99e-05	0.000612	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—ALDH1A1—kidney cancer	1.98e-05	0.000609	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—CRABP1—kidney cancer	1.95e-05	0.0006	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	1.94e-05	0.000599	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—CCBL1—kidney cancer	1.9e-05	0.000586	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—PGK1—kidney cancer	1.89e-05	0.000584	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—SLC5A3—kidney cancer	1.89e-05	0.000584	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—GPC3—kidney cancer	1.87e-05	0.000576	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—LDHB—kidney cancer	1.86e-05	0.000573	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—CA2—kidney cancer	1.82e-05	0.00056	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—ITPR2—kidney cancer	1.81e-05	0.000558	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—ALAD—kidney cancer	1.77e-05	0.000546	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—ST3GAL2—kidney cancer	1.73e-05	0.000533	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—ALDH1A1—kidney cancer	1.69e-05	0.000521	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—ACHE—kidney cancer	1.65e-05	0.000509	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—GSTT1—kidney cancer	1.65e-05	0.000509	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—PPAT—kidney cancer	1.65e-05	0.000508	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—GLIPR1—kidney cancer	1.65e-05	0.000508	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—PGK1—kidney cancer	1.62e-05	0.000499	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—SLC5A3—kidney cancer	1.62e-05	0.000499	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—CA9—kidney cancer	1.61e-05	0.000497	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—LDHB—kidney cancer	1.59e-05	0.00049	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	1.57e-05	0.000485	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—SCARB1—kidney cancer	1.56e-05	0.000482	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—PTGS1—kidney cancer	1.55e-05	0.000477	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—APRT—kidney cancer	1.53e-05	0.000473	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—FH—kidney cancer	1.53e-05	0.000473	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—PSMD7—kidney cancer	1.52e-05	0.000468	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—GPC3—kidney cancer	1.44e-05	0.000444	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—BCHE—kidney cancer	1.44e-05	0.000443	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—SLC5A5—kidney cancer	1.42e-05	0.000438	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—CA2—kidney cancer	1.4e-05	0.000432	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—CA9—kidney cancer	1.38e-05	0.000424	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—SLC2A1—kidney cancer	1.37e-05	0.000423	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—CRABP1—kidney cancer	1.37e-05	0.000422	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—ALAD—kidney cancer	1.37e-05	0.000421	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	1.35e-05	0.000415	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—ST3GAL2—kidney cancer	1.33e-05	0.000411	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—ALDH1A1—kidney cancer	1.3e-05	0.000402	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—ITPR2—kidney cancer	1.27e-05	0.000393	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—PGK1—kidney cancer	1.25e-05	0.000385	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—SLC5A3—kidney cancer	1.25e-05	0.000385	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—LDHB—kidney cancer	1.22e-05	0.000378	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—POMC—kidney cancer	1.17e-05	0.000362	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—CRABP1—kidney cancer	1.17e-05	0.000361	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—GSTT1—kidney cancer	1.16e-05	0.000358	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—ACHE—kidney cancer	1.16e-05	0.000358	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—GSTP1—kidney cancer	1.14e-05	0.000353	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—SCARB1—kidney cancer	1.1e-05	0.000339	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—ITPR2—kidney cancer	1.09e-05	0.000336	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—PTGS1—kidney cancer	1.09e-05	0.000336	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—ABCB1—kidney cancer	1.08e-05	0.000334	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—PSMD7—kidney cancer	1.07e-05	0.000329	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—CA9—kidney cancer	1.06e-05	0.000328	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—GSTM1—kidney cancer	1.05e-05	0.000324	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—BCHE—kidney cancer	1.01e-05	0.000312	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—POMC—kidney cancer	1e-05	0.000309	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—SLC5A5—kidney cancer	9.99e-06	0.000308	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—CYP1A1—kidney cancer	9.96e-06	0.000307	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—ACHE—kidney cancer	9.92e-06	0.000306	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—GSTT1—kidney cancer	9.92e-06	0.000306	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—SLC2A1—kidney cancer	9.65e-06	0.000298	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—SCARB1—kidney cancer	9.39e-06	0.00029	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	9.36e-06	0.000289	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—PTGS1—kidney cancer	9.3e-06	0.000287	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—PSMD7—kidney cancer	9.12e-06	0.000281	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—CRABP1—kidney cancer	9.03e-06	0.000279	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—BCHE—kidney cancer	8.64e-06	0.000267	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—SLC5A5—kidney cancer	8.54e-06	0.000263	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—ITPR2—kidney cancer	8.4e-06	0.000259	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—SLC2A1—kidney cancer	8.24e-06	0.000254	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	8.16e-06	0.000252	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—GSTP1—kidney cancer	8.05e-06	0.000248	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	8e-06	0.000247	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—ACHE—kidney cancer	7.66e-06	0.000236	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—GSTT1—kidney cancer	7.66e-06	0.000236	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—ABCB1—kidney cancer	7.62e-06	0.000235	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—POMC—kidney cancer	7.43e-06	0.000229	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—GSTM1—kidney cancer	7.39e-06	0.000228	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—SCARB1—kidney cancer	7.25e-06	0.000224	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—PTGS1—kidney cancer	7.17e-06	0.000221	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—PSMD7—kidney cancer	7.04e-06	0.000217	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—CYP1A1—kidney cancer	7.01e-06	0.000216	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	6.98e-06	0.000215	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—GSTP1—kidney cancer	6.88e-06	0.000212	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—BCHE—kidney cancer	6.67e-06	0.000206	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—SLC5A5—kidney cancer	6.59e-06	0.000203	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—ABCB1—kidney cancer	6.51e-06	0.000201	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—SLC2A1—kidney cancer	6.36e-06	0.000196	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—GSTM1—kidney cancer	6.32e-06	0.000195	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—CYP1A1—kidney cancer	5.99e-06	0.000185	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—PTGS2—kidney cancer	5.93e-06	0.000183	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	5.76e-06	0.000178	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—GSTP1—kidney cancer	5.31e-06	0.000164	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—POMC—kidney cancer	5.23e-06	0.000161	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—PTEN—kidney cancer	5.17e-06	0.000159	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—ABCB1—kidney cancer	5.02e-06	0.000155	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	4.92e-06	0.000152	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—GSTM1—kidney cancer	4.88e-06	0.00015	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—CYP1A1—kidney cancer	4.62e-06	0.000143	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—POMC—kidney cancer	4.47e-06	0.000138	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—PTGS2—kidney cancer	4.17e-06	0.000129	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—PIK3CA—kidney cancer	3.65e-06	0.000112	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—PTEN—kidney cancer	3.64e-06	0.000112	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—PTGS2—kidney cancer	3.56e-06	0.00011	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—POMC—kidney cancer	3.45e-06	0.000106	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—PTEN—kidney cancer	3.11e-06	9.58e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—PTGS2—kidney cancer	2.75e-06	8.48e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—PIK3CA—kidney cancer	2.56e-06	7.91e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—PTEN—kidney cancer	2.4e-06	7.39e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—PIK3CA—kidney cancer	2.19e-06	6.76e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—PIK3CA—kidney cancer	1.69e-06	5.22e-05	CbGpPWpGaD
